PARPar Drugs And Chemicals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alusil, PARSIL-HT, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why buy
- • Revenue growth: 20.1% YoY
- • Profit growth: 41.9% YoY
- • Debt/Equity: 0.00
- • RSI: 62
- • MACD: bullish
- • Price vs EMA21: above
- • Bull Flag signal (setup quality 75%)
Bull case
- • Revenue growth: 20.1% YoY
- • Profit growth: 41.9% YoY
- • Debt/Equity: 0.00
- • RSI: 62
Bear case
- • Dividend yield: 0.00%
- • Supertrend: bearish
- • Volume: 0.4x 20-day average
- • Volatility: 55% annualized
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Dividend yield: 0.00%
- • Supertrend: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹9.81). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.